# Champions Oncology Announces Remarkable Lineup of Speakers at its Translational Oncology Symposium in Boston in September 2023
Canonical URL: https://biopharmsignal.com/news/CSBR/champions-oncology-announces-remarkable-lineup-of-speakers-at-its-translational--c4916c08
Ticker: CSBR
Company: Champions Oncology
Source: Champions Oncology
Published: 2026-07-08 21:06 EST
Original Source URL: https://blog.championsoncology.com/news
## Summary

Champions Oncology is hosting a Translational Oncology Symposium in Boston in September 2023.

## Article Body
HACKENSACK, NJ – August 22, 8:30 AM - Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, kicks off its annual series of events by hosting a scientific symposium at the Museum of Science, in Boston, Massachusetts on September 26 th .

This year’s event, titled “Uncovering Integrative Approaches for Oncology Drug Development” will focus on how the integrated use of clinically relevant patient-derived models, multi-omics analytics, and high-complexity phenotypical assays are impacting the entire drug development continuum across multiple therapeutic modalities.

With a remarkable lineup of nine speakers representing biopharma companies including AstraZeneca, Codagenix, Blueprint Medicines, Bicycle Therapeutics, C4 Therapeutics, and Corellia AI, talks will provide the latest insights about exciting preclinical and clinical programs and discuss the use of innovative integrated approaches to accelerate their oncology programs. The event will be opened by a distinguished keynote speaker, Dr. Olivier Elemento from Cornell Medicine, who will discuss advancements and the future of oncology precision medicine.

Champions’ Chief Executive Officer, Ronnie Morris said, “As a leading partner for both preclinical and clinical programs, Champions Oncology is proud to host an event that will bring together a renowned group of leaders in the field and enable enlightening and exciting scientific discussions, that will result in the achievement of our shared mission of improving patient’s lives”.

The symposium will feature Champions’ Senior Scientific Director, Dr. Stefano Cairo, and the Director of Flow Cytometry, Dr. Brandon Walling, presenting the latest advancement in integrative approaches using patient-derived models and high-complexity flow cytometry in translational research.

The event is proudly sponsored by Champions in partnership with BGI Americas and Emulate and is free to attend, with limited seats.

For the full agenda and to register for the upcoming symposium, visit our website at: https://www.championsoncology.com/upcoming-events/boston-symposium_2023
## Recent Company News
- 2026-07-08 21:06 EST — [Champions Oncology Reports Quarterly Revenue of $13.1 Million](https://biopharmsignal.com/news/CSBR/champions-oncology-reports-quarterly-revenue-of-13-1-million-9f7e33ee) — Source: Champions Oncology
- 2026-07-08 21:06 EST — [Champions Oncology Announces a Multi-Year Agreement & Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies](https://biopharmsignal.com/news/CSBR/champions-oncology-announces-a-multi-year-agreement-strategic-collaboration-with-c65d8149) — Source: Champions Oncology
- 2026-07-08 21:06 EST — [Champions Oncology Announces Remarkable Lineup of Speakers at its Translational Oncology Symposium in Boston in September 2023](https://biopharmsignal.com/news/CSBR/champions-oncology-announces-remarkable-lineup-of-speakers-at-its-translational--c4916c08) — Source: Champions Oncology
- 2026-07-08 21:06 EST — [News | Champions Oncology](https://biopharmsignal.com/news/CSBR/news-champions-oncology-349bd91b) — Source: Champions Oncology
- 2026-07-08 21:06 EST — [Champions Oncology Reports Quarterly Revenue of $12.6 Million](https://biopharmsignal.com/news/CSBR/champions-oncology-reports-quarterly-revenue-of-12-6-million-484f1741) — Source: Champions Oncology
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)